Adequate protein intake, both in quantity and quality, represents a critical component of preventive dietary strategies targeting sarcopenia [105, 106]
Yes, the FDAs black box warning for medullary thyroid carcinoma and MEN 2 syndrome applies to the entire class of GLP-1 receptor agonists, which include liraglutide (Saxeda and Victoza), dulaglutide (Trulicity), semaglutide (Ozempic, Rybelsus, and Wegovy), and tirzepatide (Mounjaro and Zepbound)
Intranasal administration : Employed in studies on hypothalamic IL-2 expression and cognitive outcomes, leveraging the olfactory bulb for CNS entry
This review covers what the brand claims, what published research actually supports, and - most importantly - the two specific things almost every other review in this space skips